HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $45 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Tyra Biosciences (NASDAQ:TYRA) with a Buy and maintains $45 price target.
Stocks · News reference
Tyra Biosciences shares are trading higher after HC Wainwright & Co. reiterated its Buy rating on the stock and maintained a $45 price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Tyra Biosciences To Discuss Initial Clinical Results From SURF302 Phase 2 Study Evaluating Oral Dabogratinib For IR NMIBC In Conference Call And Webcast On September 9
Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology,
Tyra Biosciences shares are trading lower after the company reported worse-than-expected Q2 EPS results.